Abstract
Nanotechnology has enabled the development of novel therapeutic and diagnostic strategies, such as advances in targeted drug delivery systems, versatile molecular imaging modalities, stimulus responsive components for fabrication, and potential theranostic agents in cancer therapy. Nanoparticle modifications such as conjugation with polyethylene glycol have been used to increase the duration of nanoparticles in blood circulation and reduce renal clearance rates. Such modifications to nanoparticle fabrication are the initial steps toward clinical translation of nanoparticles. Additionally, the development of targeted drug delivery systems has substantially contributed to the therapeutic efficacy of anti-cancer drugs and cancer gene therapies compared with nontargeted conventional delivery systems. Although multifunctional nanoparticles offer numerous advantages, their complex nature imparts challenges in reproducibility and concerns of toxicity. A thorough understanding of the biological behavior of nanoparticle systems is strongly warranted prior to testing such systems in a clinical setting. Translation of novel nanodrug delivery systems from the bench to the bedside will require a collective approach. The present review focuses on recent research efforts citing relevant examples of advanced nanodrug delivery and imaging systems developed for cancer therapy. Additionally, this review highlights the newest technologies such as microfluidics and biomimetics that can aid in the development and speedy translation of nanodrug delivery systems to the clinic.
Similar content being viewed by others
REFERENCES
Juliano R. Nanomedicine: is the wave cresting? Nat Rev Drug Discov. 2013;12(3):171–2. doi:10.1038/nrd3958.
Bourzac K. Nanotechnology: carrying drugs. Nature. 2012;491(7425):S58–60.
Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(5):1310–6. doi:10.1158/1078-0432.CCR-07-1441.
De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133–49.
Venkatraman SS, Ma LL, Natarajan JV, Chattopadhyay S. Polymer- and liposome-based nanoparticles in targeted drug delivery. Front Biosci. 2010;2:801–14.
Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771–82. doi:10.1038/nrd2614.
Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282–95. doi:10.1208/s12248-012-9339-4.
Mudshinge SR, Deore AB, Patil S, Bhalgat CM. Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2011;19(3):129–41. doi:10.1016/j.jsps.2011.04.001.
Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. doi:10.1016/j.addr.2012.09.037.
James ND, Coker RJ, Tomlinson D, Harris JR, Gompels M, Pinching AJ, et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin Oncol. 1994;6(5):294–6.
Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2007;18(4):716–21. doi:10.1093/annonc/mdl484.
Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli C, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2004;15(1):134–8.
Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother. 2002;3(12):1739–51. doi:10.1517/14656566.3.12.1739.
Liu D, He C, Wang AZ, Lin W. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomedicine. 2013;8:3309–19. doi:10.2147/IJN.S38354.
Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res. 2011;44(10):1094–104. doi:10.1021/ar200105p.
Liao Z, Wang H, Lv R, Zhao P, Sun X, Wang S, et al. Polymeric liposomes-coated superparamagnetic iron oxide nanoparticles as contrast agent for targeted magnetic resonance imaging of cancer cells. Langmuir: the ACS journal of surfaces and colloids. 2011. doi:10.1021/la1050157.
Poulose AC, Veeranarayanan S, Mohamed MS, Raveendran S, Nagaoka Y, Yoshida Y, et al. PEG coated biocompatible cadmium chalcogenide quantum dots for targeted imaging of cancer cells. J Fluoresc. 2012;22(3):931–44. doi:10.1007/s10895-011-1032-y.
Mukthavaram R, Wrasidlo W, Hall D, Kesari S, Makale M. Assembly and targeting of liposomal nanoparticles encapsulating quantum dots. Bioconjug Chem. 2011;22(8):1638–44. doi:10.1021/bc200201e.
Yang C, Ding N, Xu Y, Qu X, Zhang J, Zhao C, et al. Folate receptor-targeted quantum dot liposomes as fluorescence probes. J Drug Target. 2009;17(7):502–11. doi:10.1080/10611860903013248.
Kono K, Torikoshi Y, Mitsutomi M, Itoh T, Emi N, Yanagie H, et al. Novel gene delivery systems: complexes of fusigenic polymer-modified liposomes and lipoplexes. Gene Ther. 2001;8(1):5–12. doi:10.1038/sj.gt.3301365.
Dass CR, Choong PF. Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability. J Control Release Off J Control Release Soc. 2006;113(2):155–63. doi:10.1016/j.jconrel.2006.04.009.
Ruponen M, Honkakoski P, Ronkko S, Pelkonen J, Tammi M, Urtti A. Extracellular and intracellular barriers in non-viral gene delivery. J Control Release Off J Control Release Soc. 2003;93(2):213–7.
Yang SY, Zheng Y, Chen JY, Zhang QY, Zhao D, Han DE, et al. Comprehensive study of cationic liposomes composed of DC-Chol and cholesterol with different mole ratios for gene transfection. Colloids Surf B,Biointerfaces. 2013;101:6–13. doi:10.1016/j.colsurfb.2012.05.032.
Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther. 2004;11(11):733–9. doi:10.1038/sj.cgt.7700756.
Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PloS One. 2012;7(4):e34833. doi:10.1371/journal.pone.0034833.
Suzuki R, Namai E, Oda Y, Nishiie N, Otake S, Koshima R, et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release Official J Control Release Soc. 2010;142(2):245–50. doi:10.1016/j.jconrel.2009.10.027.
Negishi Y, Hamano N, Tsunoda Y, Oda Y, Choijamts B, Endo-Takahashi Y, et al. AG73-modified bubble liposomes for targeted ultrasound imaging of tumor neovasculature. Biomaterials. 2013;34(2):501–7. doi:10.1016/j.biomaterials.2012.09.056.
Liu J, Ma H, Wei T, Liang XJ. CO2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells. Chem Commun. 2012;48(40):4869–71. doi:10.1039/c2cc31697h.
Karanth H, Murthy RS. pH-sensitive liposomes—principle and application in cancer therapy. J Pharm Pharmacol. 2007;59(4):469–83. doi:10.1211/jpp.59.4.0001.
Gao ZG, Lee DH, Kim DI, Bae YH. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J Drug Target. 2005;13(7):391–7. doi:10.1080/10611860500376741.
Mo R, Sun Q, Li N, Zhang C. Intracellular delivery and antitumor effects of pH-sensitive liposomes based on zwitterionic oligopeptide lipids. Biomaterials. 2013;34(11):2773–86. doi:10.1016/j.biomaterials.2013.01.030.
Banerjee S, Sen K, Pal TK, Guha SK. Poly(styrene-co-maleic acid)-based pH-sensitive liposomes mediate cytosolic delivery of drugs for enhanced cancer chemotherapy. Int J Pharm. 2012;436(1–2):786–97. doi:10.1016/j.ijpharm.2012.07.059.
Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003. doi:10.1038/nmat3776.
Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target. 2008;16(2):108–23. doi:10.1080/10611860701794353.
Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1–2):113–42. doi:10.1016/j.ijpharm.2009.10.018.
Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–27. doi:10.1038/nrd2591.
Pridgen EM, Langer R, Farokhzad OC. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond). 2007;2(5):669–80. doi:10.2217/17435889.2.5.669.
Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond). 2007;2(4):415–23. doi:10.2217/17435889.2.4.415.
Dosio F, Arpicco S, Brusa P, Stella B, Cattel L. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. J Control Release Off J Control Release Soc. 2001;76(1–2):107–17.
Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(5):1606–14. doi:10.1158/1078-0432.CCR-05-1566.
Gaur S, Chen L, Yen T, Wang Y, Zhou B, Davis M, et al. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine Nanotechnol Biol Med. 2012;8(5):721–30. doi:10.1016/j.nano.2011.09.007.
Ding HM, Ma YQ. Controlling cellular uptake of nanoparticles with pH-sensitive polymers. Sci Rep. 2013;3:2804. doi:10.1038/srep02804.
Vivek R, Nipun Babu V, Thangam R, Subramanian KS, Kannan S. pH-responsive drug delivery of chitosan nanoparticles as Tamoxifen carriers for effective anti-tumor activity in breast cancer cells. Colloids Surf B Biointerfaces. 2013;111C:117–23. doi:10.1016/j.colsurfb.2013.05.018.
Kemp MM, Linhardt RJ. Heparin-based nanoparticles. Wiley Interdiscip Rev Nanomedicine Nanobiotechnol. 2010;2(1):77–87. doi:10.1002/wnan.68.
Wang Y, Xin D, Liu K, Zhu M, Xiang J. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem. 2009;20(12):2214–21. doi:10.1021/bc8003809.
Wang Y, Wang Y, Xiang J, Yao K. Target-specific cellular uptake of taxol-loaded heparin-PEG-folate nanoparticles. Biomacromolecules. 2010;11(12):3531–8. doi:10.1021/bm101013s.
Tan Q, Tang H, Hu J, Hu Y, Zhou X, Tao Y, et al. Controlled release of chitosan/heparin nanoparticle-delivered VEGF enhances regeneration of decellularized tissue-engineered scaffolds. Int J Nanomedicine. 2011;6:929–42. doi:10.2147/IJN.S18753.
Kemp MM, Kumar A, Mousa S, Dyskin E, Yalcin M, Ajayan P, et al. Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. Nanotechnology. 2009;20(45):455104. doi:10.1088/0957-4484/20/45/455104.
Yuk SH, Oh KS, Cho SH, Lee BS, Kim SY, Kwak BK, et al. Glycol chitosan/heparin immobilized iron oxide nanoparticles with a tumor-targeting characteristic for magnetic resonance imaging. Biomacromolecules. 2011;12(6):2335–43. doi:10.1021/bm200413a.
Li Li KMH, Yong-Kyu L, So Yeon K. Biofunctional self-assembled nanoparticles of folate–PEG–heparin/PBLA copolymers for targeted delivery of doxorubicin. J Mater Chem. 2011;21:15288–97.
Li L, Huh KM, Leeb YK, Kim SY. Design of a multifunctional heparin-based nanoparticle system for anticancer drug delivery. Macromol Res. 2010;18:153–61.
She W, Li N, Luo K, Guo C, Wang G, Geng Y, et al. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials. 2013;34(9):2252–64. doi:10.1016/j.biomaterials.2012.12.017.
Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond). 2010;5(4):523–8. doi:10.2217/nnm.10.23.
Yinting Chen GL, Liao C, Wang W, Zeng L, Qian C, Huang K, et al. Characterization of polyethylene glycol-grafted polyethylenimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo. J Gastroenterol. 2013;48:809–21.
Shen Y, Tang H, Zhan Y, Van Kirk EA, Murdoch WJ. Degradable poly(beta-amino ester) nanoparticles for cancer cytoplasmic drug delivery. Nanomedicine Nanotechnol Biol Med. 2009;5(2):192–201. doi:10.1016/j.nano.2008.09.003.
Kaul G, Amiji M. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target. 2004;12(9–10):585–91. doi:10.1080/10611860400013451.
van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res. 2007;24(8):1405–14. doi:10.1007/s11095-007-9284-6.
Choi KY, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials. 2011;32(7):1880–9. doi:10.1016/j.biomaterials.2010.11.010.
Dubey N, Varshney R, Shukla J, Ganeshpurkar A, Hazari PP, Bandopadhaya GP, et al. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog. Drug Deliv. 2012;19(3):132–42. doi:10.3109/10717544.2012.657718.
Kawano K, Maitani Y. Effects of polyethylene glycol spacer length and ligand density on folate receptor targeting of liposomal Doxorubicin in vitro. J Drug Deliv. 2011;2011:160967. doi:10.1155/2011/160967.
Chen J, Li S, Shen Q, He H, Zhang Y. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer. Drug Dev Ind Pharm. 2011;37(11):1339–46. doi:10.3109/03639045.2011.575162.
Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjugate chemistry. 2006;17(3):603–9. doi:10.1021/bc050335b.
Hong M, Zhu S, Jiang Y, Tang G, Sun C, Fang C, et al. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles. J Control Release Off J Control Release Soc. 2010;141(1):22–9. doi:10.1016/j.jconrel.2009.08.024.
Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65(12):5317–24. doi:10.1158/0008-5472.CAN-04-3921.
Beech JR, Shin SJ, Smith JA, Kelly KA. Mechanisms for targeted delivery of nanoparticles in cancer. Curr Pharm Des. 2013;19(37):6560–74.
Hughes BJ, Kennel S, Lee R, Huang L. Monoclonal antibody targeting of liposomes to mouse lung in vivo. Cancer Res. 1989;49(22):6214–20.
Ahmad I, Allen TM. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. 1992;52(17):4817–20.
Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release Off J Control Release Soc. 2004;100(1):135–44. doi:10.1016/j.jconrel.2004.08.007.
Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8(4):1172–81.
Maclean A, Symonds G, Ward R. Immunoliposomes as targeted delivery vehicles for cancer therapeutics (Review). Int J Oncol. 1997;11(2):325–32.
Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, et al. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. J Liposome Res. 2010;20(4):330–40. doi:10.3109/08982100903544185.
Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 2012;13(12):1234–41. doi:10.1016/S1470-2045(12)70476-X.
Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(9):3567–73. doi:10.1158/1078-0432.CCR-04-2517.
Hamaguchi T, Matsumura Y, Nakanishi Y, Muro K, Yamada Y, Shimada Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci. 2004;95(7):608–13.
Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(3):1100–11.
Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm. 2007;342(1–2):194–200. doi:10.1016/j.ijpharm.2007.04.037.
Gao J, Chen H, Yu Y, Song J, Song H, Su X, et al. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials. 2013;34(38):10084–98. doi:10.1016/j.biomaterials.2013.08.088.
Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005;5(1):111–24. doi:10.1517/14712598.5.1.111.
Vaneycken I, D'Huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, et al. Immuno-imaging using nanobodies. Curr Opin Biotechnol. 2011;22(6):877–81. doi:10.1016/j.copbio.2011.06.009.
Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J Off Publ Fed Am Soc Exp Biol. 2011;25(7):2433–46. doi:10.1096/fj.10-180331.
Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother CII. 2007;56(3):303–17. doi:10.1007/s00262-006-0180-4.
Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010;70(21):8617–29. doi:10.1158/0008-5472.CAN-10-0920.
Aravind A, Jeyamohan P, Nair R, Veeranarayanan S, Nagaoka Y, Yoshida Y, et al. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng. 2012;109(11):2920–31. doi:10.1002/bit.24558.
Mann AP, Bhavane RC, Somasunderam A, Liz Montalvo-Ortiz B, Ghaghada KB, Volk D, et al. Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget. 2011;2(4):298–304.
Sundaram P, Kurniawan H, Byrne ME, Wower J. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2013;48(1–2):259–71. doi:10.1016/j.ejps.2012.10.014.
Camp ER, Wang C, Little EC, Watson PM, Pirollo KF, Rait A, et al. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013;20(4):222–8. doi:10.1038/cgt.2013.9.
Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther J Am Soc Gene Ther. 2013;21(5):1096–103. doi:10.1038/mt.2013.32.
Alexis F, Basto P, Levy-Nissenbaum E, Radovic-Moreno AF, Zhang L, Pridgen E, et al. HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem. 2008;3(12):1839–43. doi:10.1002/cmdc.200800122.
Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(15):3910–22. doi:10.1158/1078-0432.CCR-10-0005.
Danhier F, Le Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9(11):2961–73. doi:10.1021/mp3002733.
Kumar A, Ma H, Zhang X, Huang K, Jin S, Liu J, et al. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials. 2012;33(4):1180–9. doi:10.1016/j.biomaterials.2011.10.058.
Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM, et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci U S A. 2011;108(42):17450–5. doi:10.1073/pnas.1114518108.
Agemy L, Kotamraju VR, Friedmann-Morvinski D, Sharma S, Sugahara KN, Ruoslahti E. Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32. Mol Ther J Am Soc Gene Ther. 2013. doi:10.1038/mt.2013.191.
Kelly KA, Bardeesy N, Anbazhagan R, Gurumurthy S, Berger J, Alencar H, et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 2008;5(4):e85. doi:10.1371/journal.pmed.0050085.
Yang HM, Park CW, Woo MA, Kim MI, Jo YM, Park HG, et al. HER2/neu antibody conjugated poly(amino acid)-coated iron oxide nanoparticles for breast cancer MR imaging. Biomacromolecules. 2010. doi:10.1021/bm100560m.
Oghabian MA, Jeddi-Tehrani M, Zolfaghari A, Shamsipour F, Khoei S, Amanpour S. Detectability of Her2 positive tumors using monoclonal antibody conjugated iron oxide nanoparticles in MRI. J Nanosci Nanotechnol. 2011;11(6):5340–4.
Minati Satpathy WQ, Rafal Zielinski, Liya Wang, Lei Xi, Jacek Capala, Andrew Wang, et. al. Multimodality imaging of ovarian cancer using HER2 affibody conjugated nanoparticles. Cancer Res. 2013;73:Suppl 1.
Zhang MZ, Yu RN, Chen J, Ma ZY, Zhao YD. Targeted quantum dots fluorescence probes functionalized with aptamer and peptide for transferrin receptor on tumor cells. Nanotechnology. 2012;23(48):485104. doi:10.1088/0957-4484/23/48/485104.
Cai W, Chen X. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc. 2008;3(1):89–96. doi:10.1038/nprot.2007.478.
Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58(14):1532–55. doi:10.1016/j.addr.2006.09.009.
Ventola CL. The nanomedicine revolution: part 2: current and future clinical applications. P T Peer Rev J Formul Manag. 2012;37(10):582–91.
Eliasof S, Lazarus D, Peters CG, Case RI, Cole RO, Hwang J, et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A. 2013;110(37):15127–32. doi:10.1073/pnas.1309566110.
Sahoo B, Devi KS, Banerjee R, Maiti TK, Pramanik P, Dhara D. Thermal and pH responsive polymer-tethered multifunctional magnetic nanoparticles for targeted delivery of anticancer drug. ACS Appl Mater Interfaces. 2013;5(9):3884–93. doi:10.1021/am400572b.
Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012;338(6109):903–10. doi:10.1126/science.1226338.
Nagahiro I, Mora BN, Boasquevisque CH, Scheule RK, Patterson GA. Toxicity of cationic liposome-DNA complex in lung isografts. Transplantation. 2000;69(9):1802–5.
Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release Off J Control Release Soc. 2006;114(1):100–9. doi:10.1016/j.jconrel.2006.04.014.
Miller K, Erez R, Segal E, Shabat D, Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem. 2009;48(16):2949–54. doi:10.1002/anie.200805133.
Fiering J, Mescher MJ, Leary Swan EE, Holmboe ME, Murphy BA, Chen Z, et al. Local drug delivery with a self-contained, programmable, microfluidic system. Biomed Microdevices. 2009;11(3):571–8. doi:10.1007/s10544-008-9265-5.
Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol. 2012;7(10):623–9. doi:10.1038/nnano.2012.168.
Majedi FS, Hasani-Sadrabadi MM, Emami SH, Shokrgozar MA, VanDersarl JJ, Dashtimoghadam E, et al. Microfluidic assisted self-assembly of chitosan based nanoparticles as drug delivery agents. Lab Chip. 2013;13(2):204–7. doi:10.1039/c2lc41045a.
Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108(27):10980–5. doi:10.1073/pnas.1106634108.
Zhang J, Gong M, Yang S, Gong YK. Crosslinked biomimetic random copolymer micelles as potential anti-cancer drug delivery vehicle. J Control Release Off J Control Release Soc. 2011;152 Suppl 1:e23–5. doi:10.1016/j.jconrel.2011.08.099.
Author information
Authors and Affiliations
Corresponding author
Additional information
Guest Editors: Mahavir B. Chougule and Chalet Tan
Rights and permissions
About this article
Cite this article
Babu, A., Templeton, A.K., Munshi, A. et al. Nanodrug Delivery Systems: A Promising Technology for Detection, Diagnosis, and Treatment of Cancer. AAPS PharmSciTech 15, 709–721 (2014). https://doi.org/10.1208/s12249-014-0089-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-014-0089-8